The Genome Analysis Core (GAC or the Core) provides services, advice, and instrumentation for genotyping, gene expression, and epigenetic (methylation) analysis. Using two main platforms, the Sequenom MassArray and the AB 7900HT Real-Time QPCR instrument, the Core provides a variety of services at the low- to medium-throughput level important for understanding the genetics of cancer. Genotyping and mutation analyses of single nucleotide polymorphisms (SNPs) using the Sequenom MassArray are instrumental in helping scientists determine causative mutations in the germline or somatic genes, which lead to certain cancers or human diseases. Methylation analyses provided by the Sequenom MassArray assist in understanding the control of gene expression in tumor progression. A major focus of the Core's services is the use of quantitative real-time PCR (QPCR) on the 7900HT platform. Using a repository of TaqMan assays, the Core provides services for DNA copy number measurements, mRNA and miRNA expression analyses, plus training courses for members of the Helen Diller Family Comprehensive Cancer Center (Center) to learn QPCR techniques. Besides full-service options, most instrumentation is available for independent use by investigators The Center GAC works to improve access by Center members to genetic and genomic technologies. The services we offer, or propose to develop, are actively coordinated with the other UCSF genomics core facilities to avoid detrimental duplication of capacity. For example. Center members have access to extensive high throughput gene expression, genotyping, and sequencing technologies (Affymetrix and Illumina) through Core facilities at UCSF's Parnassus and Mission Bay campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693942
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$314,546
Indirect Cost
$115,366
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications